Last reviewed · How we verify
Folinic Acid, interferon-alpha
This combination uses folinic acid to enhance interferon-alpha's immunostimulatory effects, potentially improving anti-tumor immune response.
This combination uses folinic acid to enhance interferon-alpha's immunostimulatory effects, potentially improving anti-tumor immune response. Used for Metastatic renal cell carcinoma, Metastatic melanoma.
At a glance
| Generic name | Folinic Acid, interferon-alpha |
|---|---|
| Sponsor | University of Ulm |
| Drug class | Immunotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Folinic acid (leucovorin) acts as a cofactor that enhances cellular metabolism and may potentiate interferon-alpha's antiviral and anti-proliferative properties. Interferon-alpha is a cytokine that activates natural killer cells and macrophages to mount an immune response against malignant cells. The combination is designed to leverage synergistic immunomodulatory effects in cancer treatment.
Approved indications
- Metastatic renal cell carcinoma
- Metastatic melanoma
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Hepatotoxicity
- Myelosuppression
- Neuropsychiatric effects
Key clinical trials
- Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19) (NA)
- Combination Chemotherapy in Treating Patients With Lymphoma (PHASE3)
- Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer (PHASE3)
- Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer (PHASE2)
- Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma (PHASE2)
- Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer (PHASE1)
- A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma (PHASE2)
- Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folinic Acid, interferon-alpha CI brief — competitive landscape report
- Folinic Acid, interferon-alpha updates RSS · CI watch RSS
- University of Ulm portfolio CI